Watchlist Price Alert

Moderna Inc. (MRNA)

NASDAQ: MRNA · Real-Time Price · USD

26.68

-0.67 (-2.45%)

At close: Jun 13, 2025, 3:59 PM

26.62

-0.22%

After-hours: Jun 13, 2025, 05:59 PM EDT

-2.45% (1D)

Bid	26.6
Market Cap	10.32B
Revenue (ttm)	3.16B
Net Income (ttm)	-3.36B
EPS (ttm)	-8.73
PE Ratio (ttm)	-3.06
Forward PE	-3.72
Analyst	Hold

Ask	26.65
Volume	6,399,239
Avg. Volume (20D)	10,699,433
Open	26.57
Previous Close	27.35
Day's Range	26.31 - 27.35
52-Week Range	23.15 - 145.74
Beta	1.86

About MRNA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRNA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+1.84%

Moderna shares are trading higher after the compan... Unlock content with Pro Subscription

3 weeks ago

-7.82%

Moderna shares are trading lower after the company announced it has withdrawn the pending biologics license application for mRNA-1083.

News

1 day ago · reuters.com

Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

2 days ago · reuters.com

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.

2 days ago · accessnewswire.com

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...

2 days ago · fool.com

Is it Time to Dump Your Shares of Moderna?

After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this f...

3 days ago · seekingalpha.com

Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen ...

3 days ago · accessnewswire.com

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on...

3 days ago · cnbc.com

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...

4 days ago · reuters.com

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...

4 days ago · barrons.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

4 days ago · forbes.com

What Sparked Moderna Stock Crash?

Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the Europea...

Load More News